UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(d) of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): October 11,
2018
GT Biopharma, Inc.
(Exact
name of Registrant as specified in its charter)
|
Delaware
(State
or other Jurisdiction of Incorporation or
organization)
|
000-08092
(Commission
File Number)
|
94-1620407
(IRS
Employer I.D. No.)
|
310 N. Westlake Blvd
Suite 206
Westlake Village, CA 91362
Phone: (800) 304-9888
(Address,
including zip code, and telephone number, including area code,
of
registrant’s
principal executive offices)
100 South Ashley Drive
Suite 600
Tampa, FL 33602
(Former
name, former address and former fiscal year, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule l 4a- l 2 under the Exchange Act (17 CFR 240. l
4a- l 2)
☐
Pre-commencement
communications pursuant to Rule l 4d-2(b) under the Exchange Act
(17 CFR 240. l 4d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240. l 3e-4(c))
ITEM 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On October 11, 2018, Steven Weldon resigned from the Board. Mr.
Weldon also resigned from his position as Chief Financial Officer
at GT Biopharma. This resignation was also effective as of October
11, 2018. Neither resignation involved any disagreement with the
Company.
SIGNATURE PAGE
Pursuant
to the requirement of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
GT Biopharma, Inc.
|
|
|
|
|
|
|
|
|
Dated:
October 16, 2018
|
|
By:
|
/s/Raymond W
Urbanski
|
|
|
|
|
|
Raymond
W. Urbanski
|
|
|
|
|
|
Chairman and Chief
Executive Officer
|
|